Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1

Status

Recruiting 14Active not recruiting 6Completed 3Not yet recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Kidney Neoplasms 1High-Risk Localized Prostate Cancer 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Carboplatin 75Cisplatin 73Bevacizumab 64Radiotherapy 57Drug Therapy 56Capecitabine 56tislelizumab 54Oxaliplatin 54Gemcitabine 46toripalimab 45Paclitaxel 45Specimen Handling 43sintilimab 39pembrolizumab 39anlotinib 38Cyclophosphamide 33130-nm albumin-bound paclitaxel 32Magnetic Resonance Spectroscopy 27Injections 27camrelizumab 26Pemetrexed 26Surgical Procedures, Operative 25lenvatinib 23Docetaxel 23Biopsy 23apatinib 22Etoposide 22Immune Checkpoint Inhibitors 21S 1 (combination) 20Fluorouracil 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Pluvicto × Clear all
NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

NCT06783348 2025-01-23

RENALUT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Not yet recruiting
48 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡